twoXAR Secures $10M Series A Funding to Accelerate AI-Driven Drug Discovery, Slashing Preclinical Validation Timeline to Just 3 Months

VCBeat has learned that the biomedical artificial intelligence company based in California, USAtwoXAR recently announced the completion of a $10 million Series A financing round, focusing on accelerating new drug development efficiency through big data and artificial intelligence.. This round of financing was led by SoftBank Ventures, with participation from Andreessen Horowitz Bio Fund and OS Fund.

twoXAR’s core innovation lies in AI-driven drug discovery. Its newly established drug discovery platform integrates big data, cloud computing, and artificial intelligence, offering a several-fold advantage over traditional laboratory methods by enabling faster, more cost-effective, and more precise identification of new drugs.

In terms of drug R&D models and strategies, the company leverages AI technology,Significantly shortened the cycle from identifying and confirming new drug molecules to completing preclinical validation, achieving a record-breaking timeframe of three months, and then partnered with large pharmaceutical companies to jointly advance preclinical lead candidates into clinical development.。

Mr. Andrew Radin, Co-founder and CEO of twoXAR (Image source: twoXAR official website)

“We do not choose to sell R&D tools or services to biopharmaceutical companies. Instead, we target specific new drug development projects by entering into patent licensing agreements with partners, structuring payments through upfront fees, milestone payments, and royalty fees based on the progress of drug development, thereby jointly advancing new drugs to market,” said Mr. Andrew Radin, Co-founder and CEO of twoXAR.

He revealed that the funding will be used to: advance preclinical candidate drugs for the treatment of diabetes, liver cancer, and rheumatoid arthritis; establish new R&D pipeline collaboration projects; and strengthen team building.

“Traditionally, building a drug development pipeline has been prohibitively expensive, often costing hundreds of millions of dollars and taking many years to accomplish,” said Mr. Andrew Radin. “However, the integrated application of existing biomedical big data, affordable cloud computing, and advanced algorithms can help pharmaceutical companies accelerate the establishment of their drug development pipelines, improving both timeframes and economic costs by several fold.”

twoXAR’s partners (Image source: twoXAR official website)

In the new drug development industry, there is a “Double 10” myth: it generally takes an average of about 10 years and costs approximately $1 billion to bring a new drug from the discovery of a new molecular entity to market launch. By leveraging AI-driven drug discovery and development, twoXAR may potentially break this myth, making a substantial contribution to the pharmaceutical industry.

Source: Chuangjianhui